Related Experiment Videos
A novel adjunct for COPD: Could it be type II inflammation?
1Kelly Vazquez is a nurse practitioner in Montgomery, AL.
The Nurse Practitioner
|July 31, 2026
Summary
New biologic therapies offer hope for chronic obstructive pulmonary disease (COPD) patients with an eosinophilic phenotype. These targeted treatments address limitations of traditional COPD management, improving outcomes for specific patient groups.
Area of Science:
- Pulmonology
- Immunology
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) is primarily linked to neutrophilia, but an eosinophilic component is increasingly recognized in some patients.
- Current COPD management strategies like smoking cessation and inhaled therapies have therapeutic limitations for certain individuals.
- Biologic therapies, successful in asthma, have only recently shown efficacy in COPD.
Purpose of the Study:
- To evaluate the effectiveness of biologic therapies in patients with COPD and an eosinophilic phenotype.
- To address the unmet therapeutic needs in COPD management.
- To highlight recent advancements in COPD treatment.
Main Methods:
- Clinical trials investigating biologic therapies in COPD patients with specific eosinophilic markers.
- Analysis of patient response to novel biologic agents.
- Comparison of outcomes between patients receiving biologic therapy and those on standard care.
Main Results:
- Two biologic therapies were approved in 2025 for COPD patients exhibiting an eosinophilic phenotype.
- These therapies demonstrated significant benefits for a subset of COPD patients.
- The introduction of biologics marks a new era in personalized COPD treatment.
Conclusions:
- Biologic therapy is a viable and effective treatment option for COPD patients with an eosinophilic component.
- Personalized medicine approaches, targeting specific phenotypes, are crucial for advancing COPD care.
- Further research is warranted to optimize the use of biologics in diverse COPD populations.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD: